Monte Rosa Therapeutics, Inc
GLUE · United States
Share price · GLUE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GLUE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Nov 2026-9.7%
Nothing announced by GLUE that day or the session before.
- 31 Jul 2026-27.2%
Nothing announced by GLUE that day or the session before.
- 14 Jul 2026+6.7%
Nothing announced by GLUE that day or the session before.
- 23 Jun 2026+10.9%
Nothing announced by GLUE that day or the session before.
- 12 Jun 2026+6.6%
- 2 Jun 2026-9.8%
- 12 May 2026-5.7%
Nothing announced by GLUE that day or the session before.
- 21 Apr 2026+5.5%
- 7 Jan 2026+45.4%
- 16 Dec 2025+13.4%
Share of unusual movement by asset
For each asset, the share of GLUE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (1)
2028 (1)
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $54M | $45M | $50M+ $533M short-term inv. | —-$41M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $9.0M | $48M | $95M+ $531M short-term inv. | $43M-$44M operating cash flow | report ↗ |
| 2026-Q1 | $4.2M | $44M | $165M+ $506M short-term inv. | $45M-$37M operating cash flow | report ↗ |
| 2025-Q3 | $13M | $37M | $213M+ $183M short-term inv. | $27M$100M operating cash flow | report ↗ |
| 2025-Q2 | $23M | $31M | $74M+ $221M short-term inv. | $12M-$35M operating cash flow | report ↗ |
| 2025-Q1 | $85M | $32M | $83M | —-$45M operating cash flow | report ↗ |
| 2024-Q3 | $9.2M | $28M | $130M | $24M-$21M operating cash flow | report ↗ |
| 2024-Q2 | $4.7M | $28M | $114M | $30M-$28M operating cash flow | report ↗ |
| 2024-Q1 | $1.1M | $27M | $105M | $32M-$38M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $28M | $64M | $35M-$25M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $29M | $52M | $35M-$25M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $27M | $57M | $32M-$23M operating cash flow | report ↗ |
| 2022-Q3 | — | $21M | $118M | $27M-$21M operating cash flow | report ↗ |
| 2022-Q2 | — | $21M | $109M | $26M-$21M operating cash flow | report ↗ |
| 2022-Q1 | — | $18M | $144M | $24M-$27M operating cash flow | report ↗ |
| 2021-Q3 | — | $15M | $369M | $20M-$18M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $124M | $142M | $135M+ $247M short-term inv. | $9.7M-$23M operating cash flow | report ↗ |
Monte Rosa Therapeutics reported full-year 2025 collaboration revenue of $123.67M, up 63.5% YoY, with R&D spend of $141.5M, up 16.4% YoY. The company ended the period with cash and equivalents of $134.84M and reported a net loss of $38.63M for the year.
Business updates include positive interim Phase 1 data for NEK7-directed MRT-8102 showing CRP reductions in elevated cardiovascular-risk subjects, with an expanded GFORCE-1 proof-of-concept readout expected in H2 2026 and multiple Phase 2 studies planned across CVD-risk, gout flares, and hidradenitis suppurativa. MRT-2359 interim data showed a 100% PSA response rate in mCRPC patients with AR mutations, with a Phase 2 study in combination with apalutamide anticipated in Q3 2026. Novartis is expected to initiate multiple Phase 2 studies of VAV1-directed MRT-6160, and the company guided that its cash position, following a roughly $345M upsized financing, supports operations into 2029.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 37 sales ($4.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew · Principal Accounting Officer | Open-market sale | 13 | $10.56 | $137 | Form 4 |
| 2026-07-16 | Warmuth Markus · director, President & CEO | Open-market sale | 9,500 | $23.18 | $220K | Form 4 |
| 2026-07-15 | Champoux Jennifer · Chief Operating Officer | Option exercise | 4,351 | $3.98 | $17K | Form 4 |
| 2026-07-15 | Champoux Jennifer · Chief Operating Officer | Open-market sale | 4,351 | $23.38 | $102K | Form 4 |
| 2026-07-15 | Champoux Jennifer · Chief Operating Officer | Option exercise (derivative) | 4,351 | — | — | Form 4 |
| 2026-07-06 | Townson Sharon · Chief Scientific Officer | Option exercise | 6,000 | $6.14 | $37K | Form 4 |
| 2026-07-06 | Townson Sharon · Chief Scientific Officer | Open-market sale | 5,600 | $23.25 | $130K | Form 4 |
| 2026-07-06 | Townson Sharon · Chief Scientific Officer | Open-market sale | 400 | $24.13 | $10K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 189 reporting institutions held 86.9M shares ($1.3B, 101.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | NEA Management Company, LLC | 7,692,298 | $126.5M |
| 2 | BlackRock, Inc. | 5,637,684 | $92.7M |
| 3 | TCG Crossover Management, LLC | 4,622,151 | $76.0M |
| 4 | BVF INC/IL | 4,460,886 | $73.4M |
| 5 | BAKER BROS. ADVISORS LP | 4,345,736 | $71.5M |
| 6 | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,226,809 | $69.5M |
| 7 | Vestal Point Capital, LP | 3,603,465 | $59.3M |
| 8 | STATE STREET CORP | 3,353,980 | $55.2M |
| 9 | BRAIDWELL LP | 3,206,574 | $52.7M |
| 10 | Versant Venture Management, LLC | 3,180,780 | $52.3M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 3,100,245 | $51.0M |
| 12 | AMERICAN CENTURY COMPANIES INC | 2,809,647 | $46.2M |
| 13 | SILVERARC CAPITAL MANAGEMENT, LLC | 2,002,040 | $32.9M |
| 14 | Aisling Capital Management LP | 1,555,664 | $25.6M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 1,540,812 | $25.4M |